Kalydeco just got approved to be added to the list of the Pharmaceutical Benefits Scheme (PBS) in Australia, and will become available on December 1st 2014, as announced by Australian Health Minister Pete Dutton. This means that the costs of Kalydeco will be subsidized by the Australian government, as part of its National Medicines Policy.
The Australian government is granting $174.5 million to support the supply of Kalydeco on the PBS over the next four years.
A very interesting and potentially significant study was published by a french group at the Institute Pasteur demonstrating how a bacterium manipulates its host to eradicate an opponent. They showed that a particular enzyme produced by the airways of cystic fibrosis patients is instrumental in the elimination of S. aureus by P. aeruginosa. P. aeruginosa uses the airway’s immune system to kill the S. aureus bacterium.
The scientists have demonstrated the role played in this bacterial
The Pulmonary-Allergy Drugs Advisory Committee (Ad Comm) votes 13 - 2 in favor of a label expansion for Vertex Pharmaceuticals' cystic fibrosis med Kalydeco (ivacaftor) to include the R117H mutation. This expands the approved CF mutation list to ten. (PR source: http://t.co/514NrU3K9Q )
There is an estimated 1110 patients with the R117H mutation compared to 2700 with the G551D mutation which is the main mutation treated with Kalydeco. So this is a very significant development.
Updated 10-21-2014 at 03:24 PM by ChrisBaldwin
Researchers at UC Ivine have developed a low-cost, disposable breath analysis nanotechnology device for people with cystic fibrosis. The device sends data to a smartphone in the event of a lung infection. The device can detect tiny quantities of infection in a small sample of breath. The device can also potentially detect air pollution.
The primary aim of the device is as an early warning sign for people with cystic fibrosis to seek immediate treatment and thereby prevent permanent
An interesting study performed at the Vanderbilt University demonstrated the ability of bacteria, in this case Staphylococcus aureus, to work together in a mixed population, collectively sharing nutrients to resist drugs like antibiotics.
There are many ways bacteria can develop resistance to antibiotics, and one way is by changing the way they generate energy and becoming “small colony variants”, which are small and weak. The question has always been - how do bacteria that are less